APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Infectious Coryza Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Infectious Coryza Vaccine Industry Research Report 2026

Report ID 17400258051 January 2026125 pages

Choose your research edition.

Industry ResearchInfectious Coryza Vaccine Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Infectious Coryza Vaccine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Infectious Coryza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infectious Coryza Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Infectious Coryza Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Infectious Coryza Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Infectious Coryza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Infectious Coryza Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Infectious Coryza Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Infectious Coryza Vaccine include Boehringer Ingelheim, Ceva Santé Animale, Zoetis, Harbin Pharmaceutical Group, Merck, Plyco Bioengineering Co., Ltd., Qilu Animal Health Products Co., Ltd., Qingdao Yibang Biological Engineering Co., Ltd. and Shandong Huahong Biological Engineering Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Infectious Coryza Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Doses) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Infectious Coryza Vaccine Market by Company

Boehringer Ingelheim

Ceva Santé Animale

Zoetis

Harbin Pharmaceutical Group

Merck

Plyco Bioengineering Co., Ltd.

Qilu Animal Health Products Co., Ltd.

Qingdao Yibang Biological Engineering Co., Ltd.

Shandong Huahong Biological Engineering Co., Ltd.

Shandong Lvdu Biological Technology Co., Ltd.

Tianjin Ruipu Biotechnology Co., Ltd.

Infectious Coryza Vaccine Segment by Type

Monovalent Vaccine

Bivalent Vaccine

Trivalent Vaccine

Infectious Coryza Vaccine Segment by Application

Retail

Online Sale

Others

Infectious Coryza Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Coryza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infectious Coryza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Coryza Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Infectious Coryza Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Infectious Coryza Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Infectious Coryza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Infectious Coryza Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Infectious Coryza Vaccine Sales (K Doses) of Manufacturers (2021-2026) Table 7. Global Infectious Coryza Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Infectious Coryza Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Infectious Coryza Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Infectious Coryza Vaccine Average Price (US$/Dose) of Manufacturers (2021-2026) Table 11. Global Infectious Coryza Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Infectious Coryza Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Infectious Coryza Vaccine, Product Type & Application Table 14. Global Infectious Coryza Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Infectious Coryza Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Boehringer Ingelheim Company Information Table 19. Boehringer Ingelheim Business Overview Table 20. Boehringer Ingelheim Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 21. Boehringer Ingelheim Infectious Coryza Vaccine Product Portfolio Table 22. Boehringer Ingelheim Recent Developments Table 23. Ceva Santé Animale Company Information Table 24. Ceva Santé Animale Business Overview Table 25. Ceva Santé Animale Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 26. Ceva Santé Animale Infectious Coryza Vaccine Product Portfolio Table 27. Ceva Santé Animale Recent Developments Table 28. Zoetis Company Information Table 29. Zoetis Business Overview Table 30. Zoetis Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 31. Zoetis Infectious Coryza Vaccine Product Portfolio Table 32. Zoetis Recent Developments Table 33. Harbin Pharmaceutical Group Company Information Table 34. Harbin Pharmaceutical Group Business Overview Table 35. Harbin Pharmaceutical Group Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 36. Harbin Pharmaceutical Group Infectious Coryza Vaccine Product Portfolio Table 37. Harbin Pharmaceutical Group Recent Developments Table 38. Merck Company Information Table 39. Merck Business Overview Table 40. Merck Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 41. Merck Infectious Coryza Vaccine Product Portfolio Table 42. Merck Recent Developments Table 43. Plyco Bioengineering Co., Ltd. Company Information Table 44. Plyco Bioengineering Co., Ltd. Business Overview Table 45. Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 46. Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 47. Plyco Bioengineering Co., Ltd. Recent Developments Table 48. Qilu Animal Health Products Co., Ltd. Company Information Table 49. Qilu Animal Health Products Co., Ltd. Business Overview Table 50. Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 51. Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 52. Qilu Animal Health Products Co., Ltd. Recent Developments Table 53. Qingdao Yibang Biological Engineering Co., Ltd. Company Information Table 54. Qingdao Yibang Biological Engineering Co., Ltd. Business Overview Table 55. Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 56. Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 57. Qingdao Yibang Biological Engineering Co., Ltd. Recent Developments Table 58. Shandong Huahong Biological Engineering Co., Ltd. Company Information Table 59. Shandong Huahong Biological Engineering Co., Ltd. Business Overview Table 60. Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 61. Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 62. Shandong Huahong Biological Engineering Co., Ltd. Recent Developments Table 63. Shandong Lvdu Biological Technology Co., Ltd. Company Information Table 64. Shandong Lvdu Biological Technology Co., Ltd. Business Overview Table 65. Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 66. Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 67. Shandong Lvdu Biological Technology Co., Ltd. Recent Developments Table 68. Tianjin Ruipu Biotechnology Co., Ltd. Company Information Table 69. Tianjin Ruipu Biotechnology Co., Ltd. Business Overview Table 70. Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 71. Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Product Portfolio Table 72. Tianjin Ruipu Biotechnology Co., Ltd. Recent Developments Table 73. Global Infectious Coryza Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 74. Global Infectious Coryza Vaccine Sales by Region (2021-2026) & (K Doses) Table 75. Global Infectious Coryza Vaccine Sales Market Share by Region (2021-2026) Table 76. Global Infectious Coryza Vaccine Sales by Region (2027-2032) & (K Doses) Table 77. Global Infectious Coryza Vaccine Sales Market Share by Region (2027-2032) Table 78. Global Infectious Coryza Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 79. Global Infectious Coryza Vaccine Revenue Market Share by Region (2021-2026) Table 80. Global Infectious Coryza Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 81. Global Infectious Coryza Vaccine Revenue Market Share by Region (2027-2032) Table 82. North America Infectious Coryza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. North America Infectious Coryza Vaccine Sales by Country (2021-2026) & (K Doses) Table 84. North America Infectious Coryza Vaccine Sales by Country (2027-2032) & (K Doses) Table 85. North America Infectious Coryza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Infectious Coryza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 87. Europe Infectious Coryza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Europe Infectious Coryza Vaccine Sales by Country (2021-2026) & (K Doses) Table 89. Europe Infectious Coryza Vaccine Sales by Country (2027-2032) & (K Doses) Table 90. Europe Infectious Coryza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Infectious Coryza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 92. Asia Pacific Infectious Coryza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Asia Pacific Infectious Coryza Vaccine Sales by Country (2021-2026) & (K Doses) Table 94. Asia Pacific Infectious Coryza Vaccine Sales by Country (2027-2032) & (K Doses) Table 95. Asia Pacific Infectious Coryza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 96. Asia Pacific Infectious Coryza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 97. South America Infectious Coryza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. South America Infectious Coryza Vaccine Sales by Country (2021-2026) & (K Doses) Table 99. South America Infectious Coryza Vaccine Sales by Country (2027-2032) & (K Doses) Table 100. South America Infectious Coryza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 101. South America Infectious Coryza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 102. Middle East and Africa Infectious Coryza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Middle East and Africa Infectious Coryza Vaccine Sales by Country (2021-2026) & (K Doses) Table 104. Middle East and Africa Infectious Coryza Vaccine Sales by Country (2027-2032) & (K Doses) Table 105. Middle East and Africa Infectious Coryza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 106. Middle East and Africa Infectious Coryza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 107. Global Infectious Coryza Vaccine Sales by Type (2021-2026) & (K Doses) Table 108. Global Infectious Coryza Vaccine Sales by Type (2027-2032) & (K Doses) Table 109. Global Infectious Coryza Vaccine Sales Market Share by Type (2021-2026) Table 110. Global Infectious Coryza Vaccine Sales Market Share by Type (2027-2032) Table 111. Global Infectious Coryza Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 112. Global Infectious Coryza Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 113. Global Infectious Coryza Vaccine Revenue Market Share by Type (2021-2026) Table 114. Global Infectious Coryza Vaccine Revenue Market Share by Type (2027-2032) Table 115. Global Infectious Coryza Vaccine Price by Type (2021-2026) & (US$/Dose) Table 116. Global Infectious Coryza Vaccine Price by Type (2027-2032) & (US$/Dose) Table 117. Global Infectious Coryza Vaccine Sales by Application (2021-2026) & (K Doses) Table 118. Global Infectious Coryza Vaccine Sales by Application (2027-2032) & (K Doses) Table 119. Global Infectious Coryza Vaccine Sales Market Share by Application (2021-2026) Table 120. Global Infectious Coryza Vaccine Sales Market Share by Application (2027-2032) Table 121. Global Infectious Coryza Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 122. Global Infectious Coryza Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 123. Global Infectious Coryza Vaccine Revenue Market Share by Application (2021-2026) Table 124. Global Infectious Coryza Vaccine Revenue Market Share by Application (2027-2032) Table 125. Global Infectious Coryza Vaccine Price by Application (2021-2026) & (US$/Dose) Table 126. Global Infectious Coryza Vaccine Price by Application (2027-2032) & (US$/Dose) Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Infectious Coryza Vaccine Distributors List Table 130. Infectious Coryza Vaccine Customers List Table 131. Infectious Coryza Vaccine Industry Trends Table 132. Infectious Coryza Vaccine Industry Drivers Table 133. Infectious Coryza Vaccine Industry Restraints Table 134. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Infectious Coryza Vaccine Product Image Figure 5. Global Infectious Coryza Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Infectious Coryza Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Infectious Coryza Vaccine Sales (2021-2032) & (K Doses) Figure 8. Global Infectious Coryza Vaccine Average Price (US$/Dose) & (2021-2032) Figure 9. Monovalent Vaccine Product Image Figure 10. Bivalent Vaccine Product Image Figure 11. Trivalent Vaccine Product Image Figure 12. Retail Product Image Figure 13. Online Sale Product Image Figure 14. Others Product Image Figure 15. Global Infectious Coryza Vaccine Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Infectious Coryza Vaccine, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Infectious Coryza Vaccine Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Infectious Coryza Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Infectious Coryza Vaccine Sales by Region in 2025 Figure 21. Global Infectious Coryza Vaccine Revenue by Region in 2025 Figure 22. North America Infectious Coryza Vaccine Market Size by Country in 2025 Figure 23. North America Infectious Coryza Vaccine Sales Market Share by Country (2021-2032) Figure 24. North America Infectious Coryza Vaccine Revenue Market Share by Country (2021-2032) Figure 25. United States Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Infectious Coryza Vaccine Market Size by Country in 2025 Figure 28. Europe Infectious Coryza Vaccine Sales Market Share by Country (2021-2032) Figure 29. Europe Infectious Coryza Vaccine Revenue Market Share by Country (2021-2032) Figure 30. Germany Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Netherlands Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Asia Pacific Infectious Coryza Vaccine Market Size by Country in 2025 Figure 36. Asia Pacific Infectious Coryza Vaccine Sales Market Share by Country (2021-2032) Figure 37. Asia Pacific Infectious Coryza Vaccine Revenue Market Share by Country (2021-2032) Figure 38. China Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Japan Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. South Korea Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. India Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Australia Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. China Taiwan Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South America Infectious Coryza Vaccine Market Size by Country in 2025 Figure 47. South America Infectious Coryza Vaccine Sales Market Share by Country (2021-2032) Figure 48. South America Infectious Coryza Vaccine Revenue Market Share by Country (2021-2032) Figure 49. Mexico Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Brazil Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Argentina Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Colombia Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Infectious Coryza Vaccine Market Size by Country in 2025 Figure 54. Middle East and Africa Infectious Coryza Vaccine Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Infectious Coryza Vaccine Revenue Market Share by Country (2021-2032) Figure 56. Turkey Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Infectious Coryza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Infectious Coryza Vaccine Sales Market Share by Type (2021-2032) Figure 60. Global Infectious Coryza Vaccine Revenue Market Share by Type (2021-2032) Figure 61. Global Infectious Coryza Vaccine Price (US$/Dose) by Type (2021-2032) Figure 62. Global Infectious Coryza Vaccine Sales Market Share by Application (2021-2032) Figure 63. Global Infectious Coryza Vaccine Revenue Market Share by Application (2021-2032) Figure 64. Global Infectious Coryza Vaccine Price (US$/Dose) by Application (2021-2032) Figure 65. Infectious Coryza Vaccine Value Chain Figure 66. Infectious Coryza Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Infectious Coryza Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Monovalent Vaccine
  • Bivalent Vaccine
  • Trivalent Vaccine
Applications
  • Retail
  • Online Sale
  • Others
Companies covered
  • Boehringer Ingelheim
  • Ceva Santé Animale
  • Zoetis
  • Harbin Pharmaceutical Group
  • Merck
  • Plyco Bioengineering Co., Ltd.
  • Qilu Animal Health Products Co., Ltd.
  • Qingdao Yibang Biological Engineering Co., Ltd.
  • Shandong Huahong Biological Engineering Co., Ltd.
  • Shandong Lvdu Biological Technology Co., Ltd.
  • Tianjin Ruipu Biotechnology Co., Ltd.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Infectious Coryza Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Infectious Coryza Vaccine Sales (2021-2032)
  5. 2.2.3 Global Infectious Coryza Vaccine Market Average Price (2021-2032)
  6. 2.3 Infectious Coryza Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Monovalent Vaccine
  9. 2.3.3 Bivalent Vaccine
  10. 2.3.4 Trivalent Vaccine
  11. 2.4 Infectious Coryza Vaccine by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Retail
  14. 2.4.3 Online Sale
  15. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Infectious Coryza Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Infectious Coryza Vaccine Sales (K Doses) of Manufacturers (2021-2026)
  3. 3.3 Global Infectious Coryza Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Infectious Coryza Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Infectious Coryza Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Infectious Coryza Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Infectious Coryza Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Infectious Coryza Vaccine, Established Date
  9. 3.9 Global Infectious Coryza Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Boehringer Ingelheim
  2. 4.1.1 Boehringer Ingelheim Company Information
  3. 4.1.2 Boehringer Ingelheim Business Overview
  4. 4.1.3 Boehringer Ingelheim Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Boehringer Ingelheim Infectious Coryza Vaccine Product Portfolio
  6. 4.1.5 Boehringer Ingelheim Recent Developments
  7. 4.2 Ceva Santé Animale
  8. 4.2.1 Ceva Santé Animale Company Information
  9. 4.2.2 Ceva Santé Animale Business Overview
  10. 4.2.3 Ceva Santé Animale Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Ceva Santé Animale Infectious Coryza Vaccine Product Portfolio
  12. 4.2.5 Ceva Santé Animale Recent Developments
  13. 4.3 Zoetis
  14. 4.3.1 Zoetis Company Information
  15. 4.3.2 Zoetis Business Overview
  16. 4.3.3 Zoetis Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Zoetis Infectious Coryza Vaccine Product Portfolio
  18. 4.3.5 Zoetis Recent Developments
  19. 4.4 Harbin Pharmaceutical Group
  20. 4.4.1 Harbin Pharmaceutical Group Company Information
  21. 4.4.2 Harbin Pharmaceutical Group Business Overview
  22. 4.4.3 Harbin Pharmaceutical Group Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Harbin Pharmaceutical Group Infectious Coryza Vaccine Product Portfolio
  24. 4.4.5 Harbin Pharmaceutical Group Recent Developments
  25. 4.5 Merck
  26. 4.5.1 Merck Company Information
  27. 4.5.2 Merck Business Overview
  28. 4.5.3 Merck Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Merck Infectious Coryza Vaccine Product Portfolio
  30. 4.5.5 Merck Recent Developments
  31. 4.6 Plyco Bioengineering Co., Ltd.
  32. 4.6.1 Plyco Bioengineering Co., Ltd. Company Information
  33. 4.6.2 Plyco Bioengineering Co., Ltd. Business Overview
  34. 4.6.3 Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Plyco Bioengineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  36. 4.6.5 Plyco Bioengineering Co., Ltd. Recent Developments
  37. 4.7 Qilu Animal Health Products Co., Ltd.
  38. 4.7.1 Qilu Animal Health Products Co., Ltd. Company Information
  39. 4.7.2 Qilu Animal Health Products Co., Ltd. Business Overview
  40. 4.7.3 Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Qilu Animal Health Products Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  42. 4.7.5 Qilu Animal Health Products Co., Ltd. Recent Developments
  43. 4.8 Qingdao Yibang Biological Engineering Co., Ltd.
  44. 4.8.1 Qingdao Yibang Biological Engineering Co., Ltd. Company Information
  45. 4.8.2 Qingdao Yibang Biological Engineering Co., Ltd. Business Overview
  46. 4.8.3 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  48. 4.8.5 Qingdao Yibang Biological Engineering Co., Ltd. Recent Developments
  49. 4.9 Shandong Huahong Biological Engineering Co., Ltd.
  50. 4.9.1 Shandong Huahong Biological Engineering Co., Ltd. Company Information
  51. 4.9.2 Shandong Huahong Biological Engineering Co., Ltd. Business Overview
  52. 4.9.3 Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Shandong Huahong Biological Engineering Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  54. 4.9.5 Shandong Huahong Biological Engineering Co., Ltd. Recent Developments
  55. 4.10 Shandong Lvdu Biological Technology Co., Ltd.
  56. 4.10.1 Shandong Lvdu Biological Technology Co., Ltd. Company Information
  57. 4.10.2 Shandong Lvdu Biological Technology Co., Ltd. Business Overview
  58. 4.10.3 Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Shandong Lvdu Biological Technology Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  60. 4.10.5 Shandong Lvdu Biological Technology Co., Ltd. Recent Developments
  61. 4.11 Tianjin Ruipu Biotechnology Co., Ltd.
  62. 4.11.1 Tianjin Ruipu Biotechnology Co., Ltd. Company Information
  63. 4.11.2 Tianjin Ruipu Biotechnology Co., Ltd. Business Overview
  64. 4.11.3 Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Tianjin Ruipu Biotechnology Co., Ltd. Infectious Coryza Vaccine Product Portfolio
  66. 4.11.5 Tianjin Ruipu Biotechnology Co., Ltd. Recent Developments
5 Global Infectious Coryza Vaccine Market Scenario by Region
  1. 5.1 Global Infectious Coryza Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Infectious Coryza Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Infectious Coryza Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Infectious Coryza Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Infectious Coryza Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Infectious Coryza Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Infectious Coryza Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Infectious Coryza Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Infectious Coryza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Infectious Coryza Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Infectious Coryza Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Infectious Coryza Vaccine Market Facts & Figures by Country
  15. 5.5.1 Europe Infectious Coryza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Infectious Coryza Vaccine Sales by Country (2021-2032)
  17. 5.5.3 Europe Infectious Coryza Vaccine Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Infectious Coryza Vaccine Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Infectious Coryza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Infectious Coryza Vaccine Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Infectious Coryza Vaccine Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Infectious Coryza Vaccine Market Facts & Figures by Country
  35. 5.7.1 South America Infectious Coryza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Infectious Coryza Vaccine Sales by Country (2021-2032)
  37. 5.7.3 South America Infectious Coryza Vaccine Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.7.7 Colombia
  42. 5.8 Middle East and Africa Infectious Coryza Vaccine Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Infectious Coryza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Infectious Coryza Vaccine Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Infectious Coryza Vaccine Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Infectious Coryza Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Infectious Coryza Vaccine Sales by Type (2021-2032) & (K Doses)
  3. 6.1.2 Global Infectious Coryza Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Infectious Coryza Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Infectious Coryza Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Infectious Coryza Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Infectious Coryza Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Infectious Coryza Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Infectious Coryza Vaccine Sales by Application (2021-2032) & (K Doses)
  3. 7.1.2 Global Infectious Coryza Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Infectious Coryza Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Infectious Coryza Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Infectious Coryza Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Infectious Coryza Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Infectious Coryza Vaccine Value Chain Analysis
  2. 8.1.1 Infectious Coryza Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Infectious Coryza Vaccine Production Mode & Process
  5. 8.2 Infectious Coryza Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Infectious Coryza Vaccine Distributors
  8. 8.2.3 Infectious Coryza Vaccine Customers
9 Global Infectious Coryza Vaccine Analyzing Market Dynamics
  1. 9.1 Infectious Coryza Vaccine Industry Trends
  2. 9.2 Infectious Coryza Vaccine Industry Drivers
  3. 9.3 Infectious Coryza Vaccine Industry Opportunities and Challenges
  4. 9.4 Infectious Coryza Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst